<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535391</url>
  </required_header>
  <id_info>
    <org_study_id>CML0811</org_study_id>
    <secondary_id>2011-002787-25</secondary_id>
    <nct_id>NCT01535391</nct_id>
  </id_info>
  <brief_title>Nilotinib in PH+, BCR-, ABL+ CML Patients</brief_title>
  <acronym>CML0811</acronym>
  <official_title>The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+, BCR-, ABL+ Chronic Myeloid Leukemia (CML) in Early Chronic Phase: a Phase IIIb, Multicenter Study to Assess the Complete Molecular Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multicentric, phase IIIb study of NILOTINIB administered orally
      twice daily for 24 months and indefinitely if it is in the interest of the patient.

      The primary objective of the trial is to evaluate the efficacy of nilotinib, 300 mg twice
      daily with dose increase to 400 mg twice daily in case of suboptimal response or failure
      (excluding patients who will fail for progression to ABP), in a population of patients with
      Ph-positive, BCR-ABL positive CML in early CP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, multicentric, phase IIIb study of NILOTINIB administered orally
      at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core),
      and indefinitely if it is in the interest of the patient (the drug will be given
      free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in
      absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal
      response or failure (with the exception of patients who will fail for progression to ABP: in
      case of progression to ABP, the patient will not be treated with study drug and the choice of
      the treatment will be up to the physician).

      Study duration is estimated in 6 years, 1 year of estimated enrollment, 2 years therapy
      duration. Thereafter, information on course and survival is due for other 3 years.

      The main data analysis will be performed when all patients will complete 24 months of
      treatment (or discontinued earlier). Safety and tolerability profile will be assessed by
      collecting hematologic and non-hematologic adverse events, laboratory examinations and ECG
      data. The molecular response will be assessed using the GIMEMA standardized molecular
      laboratories (Labnet network).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete molecular response</measure>
    <time_frame>At 24 months of treatment</time_frame>
    <description>To assess the complete molecular response (CMR4) rate at 24 months of treatment. For the purpose of this protocol, CMR is defined as a negative results of quantitative RT-PCR for BCR-ABL transcripts in a peripheral blood sample of at least 10 ml with a minimum sensitivity of 1:10,000, that corresponds to at least a 4-log reduction (hence, CMR4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>At three years from study entry</time_frame>
    <description>Number of toxic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>At 3 years from study entry</time_frame>
    <description>Number of fully compliant patients and number of patients who do not comply with treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The complete cytogenetic response (CCgR) rate</measure>
    <time_frame>At 3, 6, 12, 18 and 24 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate and the degree of molecular response</measure>
    <time_frame>At 3, 6, 12, 18 and 24 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to CCgR, the time to MMR and the time to CMR</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At three years from study entry</time_frame>
    <description>From the date of the first nilotinib dose to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>At three years from study entry</time_frame>
    <description>From the date of the first nilotinib dose to progression to AP or BP or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure Free Survival (FFS)</measure>
    <time_frame>At three years from study entry</time_frame>
    <description>From the date of the first nilotinib dose to failure* or progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>At three years from study entry</time_frame>
    <description>From the date of the first nilotinib to any event. Including treatment discontinuation for adverse events, failure, progression to AP or BP, or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life (QoL)</measure>
    <time_frame>At baseline and then at 3, 6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  Male or female patients with diagnosis of Ph+ and/or BCR-ABL+ CML

          -  Early chronic phase (within 6 months from diagnosis)

          -  Pretreatment with Hydroxyurea or Anagrelide for a duration of up to 3 months and/or
             pretreatment with Imatinib for up to 30 days are permitted

          -  Normal serum levels of potassium, magnesium, phosphorus, total calcium corrected for
             serum albumin or phosphorus, or correctable to within normal limits with supplements
             prior to the first dose of study medication

          -  Written informed consent prior to any study procedures being performed

          -  AST and ALT ≤ 2.5 x ULN or ≤ 5.0 x ULN if considered due to leukaemia

          -  Alkaline phosphatase ≤ 2.5 x ULN unless considered due to leukaemia

          -  Total direct bilirubin ≤ 1.5 x ULN, except know Mb. Gilbert

          -  Serum creatinine ≤ 1.5 x ULN

        Exclusion Criteria:

          -  Known impaired cardiac function, including any of the following:

          -  LVEF &lt; 45%

          -  Complete left bundle branch block

          -  Right bundle branch block plus left anterior hemiblock, bifascicular block

          -  Use of a ventricular-paced pacemaker

          -  Congenital long QT syndrome

          -  History of or presence of clinically significant ventricular or atrial
             tachyarrhythmias

          -  Clinically significant resting bradycardia (&lt;50 beats per minute)

          -  QTc&gt;450 msec on screening ECG. If QTc &gt; 450 msec and electrolytes are not within
             normal ranges before Nilotinib dosing, electrolytes should be corrected and then the
             patient rescreened for QTc criterion.

          -  Myocardial infarction within 12 months prior to starting study drugs

          -  Other clinical significant heart disease (e.g. unstable angina, congestive heart
             failure, uncontrolled hypertension)

          -  Serum lipase and amylase &gt; 1.5 x ULN (upper limit of normal) or history of acute
             (i.e., within 1 year of starting study medication) or chronic pancreatitis

          -  Other concurrent uncontrolled medical conditions (e.g., uncontrolled diabetes, active
             or uncontrolled infections, acute or chronic liver and renal disease) that could cause
             unacceptable safety risks or compromise compliance with the protocol

          -  Impaired gastrointestinal function or disease that may alter the absorption of study
             drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea,
             malabsorption syndrome, small bowel resection or gastric by-pass surgery)

          -  Concomitant medications with potential QT prolongation (see link for complete list:
             http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm)

          -  Concomitant medications known to interact with CYP450 isoenzymes (CYP3A4,
             CYP2C9,andCYP2C8:link for complete list:
             http://medicine.iupui.edu/flockhart/table.html..

          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy

          -  Patients who are pregnant or breast feeding, or women of reproductive potential not
             employing an effective method of birth control. (Women of childbearing potential must
             have a negative serum pregnancy test within 48 hours prior to administration of
             nilotinib).

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention.

          -  Patients unwilling or unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianantonio Rosti</last_name>
    <role>Study Chair</role>
    <affiliation>Dpt of Hematology and Oncology, &quot;Seràgnoli&quot;, Sant'Orsola-Malpighi. University Hospital of Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.G. Moscati Hospital</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia e Fisiopatologia delle Emostasi - Azienda Ospedaliera - Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - DiMI - Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia 1 - Azienda Ospedaliera Universitaria &quot;San Martino&quot;</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia- Ospedale dell'Angelo - Mestre</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese - Dipartimento di Oncoematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia di Muraglia -CTMO Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di riferimento Oncologico di Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Ematolgia - A.O. &quot; SS Annunziata&quot; - P.O. S.G. Moscati</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDO Ematologia 2 AOU S.Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL 9 Treviso - U.O. di Ematologia</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukemia,</keyword>
  <keyword>Nilotinib,</keyword>
  <keyword>Philadelphia positive,</keyword>
  <keyword>BCR-ABL+</keyword>
  <keyword>Early chronic phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

